Opko Health Inc. (OPK, Financial) CEO, Chairman and 10% owner Phillip Frost M.D. et al bought 16,000 shares on June 14 at a price of $9.01 per share. The total transaction amount was $144,160.
Opko Health has a market cap of $5.04 billion; its shares were traded around $9.20 with a P/E ratio of 65.69 and P/S ratio of 6.26. Opko Health had an annual average earnings growth of 11.00% over the past 10 years.
Opko Health stock prices have increased over the past 10 years. The company’s revenue was relatively constant until around the end of 2014 when revenues grew sharply. This continuing revenue growth could be attributed to Opko Health’s acquisition of Bio-Reference in 2015. Opko Health has reported net losses for almost all of the last 10 years.
GuruFocus has found three severe warning signs for Opko:
- Beneish M-Score indicates that this company may be a possible manipulator of its financial results.
- Declining operating margin.
- Assets are growing faster than revenue.
Opko Health reported its 2016 first financial quarter results. The company declared revenues of $291.0 million, compared to last year’s revenues of $30.1 million. Opko Health also recognized net loss of $12.0 million, compared to last year’s net loss of $117.1 million.
Recent trades
GuruFocus gurus George Soros (Trades, Portfolio) and Mario Gabelli (Trades, Portfolio) both kept their positions in Opko Health unchanged or slightly adjusted. Soros owns 235,600 shares and Gabelli owns 11,000 shares.
Frost bought 47,600 shares of Opko stock in June. Executive VP-Administration Steven D. Rubin and Vice Chairman and CTO Jane Hsiao, Ph.D., bought 7,000 shares of Opko stock altogether in March.
Start a free seven-day trial of Premium Membership to GuruFocus.
